Characteristic MIR-24 Expression in Gastric Cancers among Atomic Bomb Survivors

Pathobiology

Volumn 82, Issue 2, 2015, Pages 68-75

  Naito, Yutaka ^a   Oue, Naohide ^a   Pham, Trang T B ^a   Yamamoto, Manabu ^d   Fujihara, Megumu ^b   Ishida, Teruyoshi ^b   Mukai, Shoichiro ^a   Sentani, Kazuhiro ^a   Sakamoto, Naoya ^a   Hida, Eisuke ^c   Sasaki, Hiroki ^e   Yasui, Wataru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Atomic bomb; Gastric cancer; microRNA; MIR 24; Radiation carcinogenesis

Indexed keywords

MICRORNA; MICRORNA 106A; MICRORNA 143; MICRORNA 145; MICRORNA 21; MICRORNA 24; MICRORNA 34A; RNA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN24 MICRORNA, HUMAN;

AGED; ARTICLE; ATOMIC BOMB; ATOMIC BOMB SURVIVOR; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; ADULT; GENETICS; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; STOMACH TUMOR; SURVIVOR;

ADULT; AGED; BIOMARKERS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NUCLEAR WEAPONS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVORS;

EID: 84930513159     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000398809     Document Type: Article

References (29)

1. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K: Studies of mortality of atomic bomb survivors. Report 13. Solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003; 160: 381-407.
2. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, Sugimoto S, Ikeda T, Terasaki M, Izumi S, et al: Cancer incidence in atomic bomb survivors. Part II. Solid tumors, 1958-1987. Radiat Res 1994; 137:S17-S67.
3. Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y, Oue N: Molecular pathology of gastric cancer: research and practice. Pathol Res Pract 2011; 207: 608-612.
4. Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, Mabuchi K, Land CE, Harris CC: p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet 1993; 342: 1520-1521.
5. Takahashi K, Eguchi H, Arihiro K, Ito R, Koyama K, Soda M, Cologne J, Hayashi Y, Nakata Y, Nakachi K, Hamatani K: The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog 2007; 46: 242-248.
6. Iwamoto KS, Mizuno T, Tokuoka S, Mabuchi K, Seyama T: Frequency of p53 mutations in hepatocellular carcinomas from atomic bomb survivors. J Natl Cancer Inst 1998; 90: 1167-1168.
7. Oue N, Sentani K, Sakamoto N, Motoshita J, Nishisaka T, Fukuhara T, Matsuura H, Sasaki H, Nakachi K, Yasui W: Characteristic gene expression in stromal cells of gastric cancers among atomic-bomb survivors. Int J Cancer 2009; 124: 1112-1121.
8. Huntzinger E, Izaurralde E: Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12: 99-110.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, et al: MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
10. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
11. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol 2010; 11: 136-146.
12. Srinivasan M, Sedmak D, Jewell S: Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002; 161: 1961-1971.
13. Specht K, Richter T, Müller U, Walch A, Werner M, Höfler H: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001; 158: 419-429.
14. Preston DL, Pierce DA, Shimizu Y, Cullings HM, Fujita S, Funamoto S, Kodama K: Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res 2004; 162: 377-389.
15. Sobin LH, Compton CC: TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 2010; 116: 5336-5339.
16. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
17. Duan Y, Hu L, Liu B, Yu B, Li J, Yan M, Yu Y, Li C, Su L, Zhu Z, Xiang M, Liu B, et al: Tumor suppressor miR-24 restrains gastric cancer progression by downregulating RegIV. Mol Cancer 2014; 13: 127.
18. Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, Meire E, Bentwich Z, Lieberman J, Chowdhury D: miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol 2009; 16: 492-498.
19. Sochor M, Basova P, Pesta M, Dusilkova N, Bartos J, Burda P, Pospisil V, Stopka T: Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer 2014; 14: 448.
20. Du WW, Fang L, Li M, Yang X, Liang Y, Peng C, Qian W, O'Malley YQ, Askeland RW, Sugg SL, Qian J, Lin J, et al: MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci 2013; 126: 1440-1453.
21. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374.
22. Van Gent DC, Hoeijmakers JH, Kanaar R: Chromosomal stability and the DNA doublestranded break connection. Nat Rev Genet 2001; 2: 196-206.
23. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM: Quantitative detection of (125) IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res 2002; 158: 486-492.
24. Sentani K, Oue N, Sakamoto N, Nishisaka T, Fukuhara T, Matsuura H, Yasui W: Positive immunohistochemical staining of gamma-H2AX is associated with tumor progression in gastric cancers from radiation-exposed patients. Oncol Rep 2008; 20: 1131-1136.
25. Vagenas K, Spyropoulos C, Gavala V, Tsamandas AC: TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. J Surg Res 2007; 139: 182-188.
26. Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, Lebaron RG, Horsfall DJ: Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 2001; 61: 926-930.
27. Reed MJ, Vernon RB, Abrass IB, Sage EH: TGF-beta 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. J Cell Physiol 1994; 158: 169-179.
28. Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, et al: Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012; 14: 249-256.
29. Naito Y, Sakamoto N, Oue N, Yashiro M, Sentani K, Yanagihara K, Hirakawa K, Yasui W: MicroRNA-143 regulates collagen type III expression in stromal fibroblasts of scirrhous type gastric cancer. Cancer Sci 2014; 105: 228-235.